Crestor

Content

Get tough with cholesterol.
Rosuvastatin is a member of the drug class of statins, used to treat high cholesterol and related conditions, and to prevent cardiovascular disease. Shionogi developed the product and the pharmaceutical company AstraZeneca markets it as Crestor.

Rosuvastatin is approved for the treatment of high LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia) and/or triglycerides (hypertriglyceridemia).

As of 2004, rosuvastatin had been approved in 154 countries and launched in 56. Approval in the United States by the FDA came on August 12, 2003.


In 2008, research emerged that rosuvastatin could reduce the risk of heart attack, stroke, and other vascular complications in patients with elevated C-reactive protein but no other risk factors. This could strongly impact medical practice by placing many patients on statin prophylaxis that otherwise would have been untreated.


The results of the JUPITER trial suggested that rosuvastatin may decrease the relative risk of heart attack and stroke in patients without hyperlipidemia.

The AURORA trial randomized 2776 patients undergoing hemodialysis to receive either rosuvastatin or placebo. The randomized, double-blind study found no difference in the two groups in the primary end point, a combination of cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke. The study found no difference in all-cause mortality among this population at a mean follow up of 3.8 years.

Brand name: Crestor
Generic name/category: Rosuvastatin, statins
Company: AstraZeneca
Country/Market: Canada, North America
Indication(s)/Category: high LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia) and/or triglycerides (hypertriglyceridemia)
Target: Healthcare Professionals (HCP)
Tagline: Count on Crestor
Publication: The Canadian Journal of Diagnosis - June 2009
Brand files